Q-omics provides the consensus-scored NPIPA7 profile across patient tissues and cancer cell-line models. NPIPA7 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NPIPA7 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, NPIPA7 RNA expression shows 3,598 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, and STAD as cancer lineages where NPIPA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPA7 survival associations across molecular data types. NPIPA7 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPA7 RNA expression–survival associations across cancer types. High NPIPA7 expression shows unfavorable associations in LUSC, UCEC, LGG, LUAD and SKCM, but favorable associations in CESC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for NPIPA7 RNA expression.
This table summarizes NPIPA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPA7 shows lower tumor expression in LUSC. The LUSC box plot shows higher NPIPA7 RNA expression in normal versus tumor tissue (log2 FC = −0.023, t-test p = .033).
This table shows molecular features associated with NPIPA7 in patient tissues and cancer cell lines. In patient samples, NPIPA7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
